基于生物标志物预测阿尔茨海默病纵向Tau蛋白正电子发射断层成像
这项纵向队列研究连续纳入瑞典BioFINDER-2和BioFINDER-1研究中淀粉样蛋白β阴性认知正常、淀粉样蛋白β阳性认知正常、淀粉样蛋白β阳性轻度认知障碍及阿尔茨海默病痴呆个体,发现血浆p-tau217联合tau PET可减少模拟临床试验样本量,在临床前阿尔茨海默病中血浆p-tau217最重要,在前驱期阿尔茨海默病中tau PET更重要。
要点
- 淀粉样蛋白β阳性认知正常者tau PET年增幅最大在I期(内嗅皮层、海马和杏仁核)
- 淀粉样蛋白β阳性轻度认知障碍者tau PET年增幅最大在II期(颞叶皮层区域)
- 淀粉样蛋白β阳性阿尔茨海默病痴呆者tau PET年增幅最大在IV期(某些额叶区域)
核心结论
- 在以tau PET为结局的试验中,血浆p-tau217联合tau PET可能对临床前和前驱期阿尔茨海默病的富集达到最优。
- 血浆p-tau217在临床前阿尔茨海默病中最重要,而tau PET在前驱期阿尔茨海默病中更重要。
研究设计与样本
- 这项纵向队列研究于2017年9月至2020年11月从瑞典BioFINDER-2(发现队列)和BioFINDER-1(验证队列)研究中连续纳入淀粉样蛋白β阴性认知正常参与者、淀粉样蛋白β阳性认知正常个体、淀粉样蛋白β阳性轻度认知障碍个体和阿尔茨海默病痴呆个体。
- 共343名参与者,平均(标准差)年龄72.56(7.24)岁,女性157名(51.1%)。
- 基线暴露包括血浆和脑脊液淀粉样蛋白β42/淀粉样蛋白β40、苏氨酸217磷酸化tau(p-tau217)、p-tau181和神经丝轻链、磁共振成像、淀粉样蛋白PET([18F]氟替美他莫)和tau PET(BioFINDER-2研究中使用[18F]RO948;BioFINDER-1研究中使用[18F]氟他西匹)。
主要发现
- 在淀粉样蛋白β阳性认知正常个体中,tau PET标准化摄取值比率年增幅最大在I期(内嗅皮层、海马和杏仁核;4.04%[95%CI,2.67%-5.32%])。
- 在淀粉样蛋白β阳性轻度认知障碍个体中,tau PET标准化摄取值比率年增幅最大在II期(颞叶皮层区域;4.45%[95%CI,3.41%-5.49%])。
- 在淀粉样蛋白β阳性阿尔茨海默病痴呆个体中,tau PET标准化摄取值比率年增幅最大在IV期(某些额叶区域;5.22%[95%CI,3.95%-6.49%])。
- 在淀粉样蛋白β阴性认知正常个体和淀粉样蛋白β阴性轻度认知障碍个体中,I期分别见1.38%(95%CI,0.78%-1.99%)和1.80%(95%CI,0.76%-2.84%)的适度变化。
- 在淀粉样蛋白β阳性认知正常个体中,血浆p-tau217(R²=0.27,P<.005)、tau PET(I期基线标准化摄取值比率;R²=0.13,P<.05)和淀粉样蛋白PET(R²=0.10,P<.05)与I期纵向tau PET显著相关;在淀粉样蛋白β阳性轻度认知障碍个体中,血浆p-tau217(R²=0.24,P<.005)和tau PET(II期基线标准化摄取值比率;R²=0.44,P<.001)与II期纵向tau PET显著相关。
关键数值与推荐
- 聚类和事件建模方法识别出5个感兴趣区域(分期)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is currently no consensus as to which biomarkers best predict longitudinal tau accumulation at different clinical stages of Alzheimer disease (AD). OBJECTIVE: To describe longitudinal [18F]RO948 tau positron emission tomography (PET) findings across the clinical continuum of AD and determine which biomarker combinations showed the strongest associations with longitudinal tau PET and best optimized clinical trial enrichment. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal cohort study consecutively enrolled amyloid-β (Aβ)-negative cognitively unimpaired (CU) participants, Aβ-positive CU individuals, Aβ-positive individuals with mild cognitive impairment (MCI), and individuals with AD dementia between September 2017 and November 2020 from the Swedish BioFINDER-2 (discovery cohort) and BioFINDER-1 (validation cohort) studies. EXPOSURES: Baseline plasma and cerebrospinal fluid Aβ42/Aβ40, tau phosphorylated at threonine-217 (p-tau217), p-tau181 and neurofilament light, magnetic resonance imaging, amyloid PET ([18F]flutemetamol), and tau PET ([18F]RO948 in the BioFINDER-2 study; [18F]flortaucipir in the BioFINDER-1 study). MAIN OUTCOMES AND MEASURES: Baseline tau PET standardized uptake value ratio (SUVR) and annual percent change in tau PET SUVR across regions of interest derived using a data-driven approach combining clustering and event-based modeling. Regression models were used to examine associations between individual biomarkers and longitudinal tau PET and to identify which combinations best predicted longitudinal tau PET. These combinations were then entered in a power analysis to examine how their use as an enrichment strategy would affect sample size in a simulated clinical trial. RESULTS: Of 343 participants, the mean (SD) age was 72.56 (7.24) years, and 157 (51.1%) were female. The clustering/event-based modeling-based approach identified 5 regions of interest (stages). In Aβ-positive CU individuals, the largest annual increase in tau PET SUVR was seen in stage I (entorhinal cortex, hippocampus, and amygdala; 4.04% [95% CI, 2.67%-5.32%]). In Aβ-positive individuals with MCI and with AD dementia, the greatest increases were seen in stages II (temporal cortical regions; 4.45% [95% CI, 3.41%-5.49%]) and IV (certain frontal regions; 5.22% [95% CI, 3.95%-6.49%]), respectively. In Aβ-negative CU individuals and those with MCI, modest change was seen in stage I (1.38% [95% CI, 0.78%-1.99%] and 1.80% [95% CI, 0.76%-2.84%], respectively). When looking at individual predictors and longitudinal tau PET in the stages that showed most change, plasma p-tau217 (R2 = 0.27, P < .005), tau PET (stage I baseline SUVR; R2 = 0.13, P < .05) and amyloid PET (R2 = 0.10, P < .05) were significantly associated with longitudinal tau PET in stage I in Aβ-positive CU individuals. In Aβ-positive individuals with MCI, plasma p-tau217 (R2 = 0.24, P < .005) and tau PET (stage II baseline SUVR; R2 = 0.44, P < .001) were significantly associated with longitudinal tau PET in stage II. Findings were replicated in BioFINDER-1 using longitudinal [18F]flortaucipir. For the power analysis component, plasma p-tau217 with tau PET resulted in sample size reductions of 43% (95% CI, 34%-46%; P < .005) in Aβ-positive CU individuals and of 68% (95% CI, 61%-73%; P < .001) in Aβ-positive individuals with MCI. CONCLUSIONS AND RELEVANCE: In trials using tau PET as the outcome, plasma p-tau217 with tau PET may prove optimal for enrichment in preclinical and prodromal AD. However, plasma p-tau217 was most important in preclinical AD, while tau PET was more important in prodromal AD.
引用
- Leuzy A, Smith R, Cullen NC, et al. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurol. 2022. PMID: 34928318. doi:10.1001/jamaneurol.2021.4654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。